Explore

Trendline Trendline
BioNTech Reduces COVID-19 Vaccine Production, Resulting in Job Cuts

BioNTech Reduces COVID-19 Vaccine Production, Resulting in Job Cuts

BioNTech Reduces COVID-19 Vaccine Production, Resulting in Job Cuts
Trendline Trendline
BioNTech to Halt COVID-19 Vaccine Production, Resulting in Significant Job Cuts

BioNTech to Halt COVID-19 Vaccine Production, Resulting in Significant Job Cuts

BioNTech to Halt COVID-19 Vaccine Production, Resulting in Significant Job Cuts
Trendline Trendline
Amazon Phases Out Local Fulfillment in Singapore, Impacting Workforce and Amazon Fresh Service

Amazon Phases Out Local Fulfillment in Singapore, Impacting Workforce and Amazon Fresh Service

Amazon Phases Out Local Fulfillment in Singapore, Impacting Workforce and Amazon Fresh Service
Trendline Trendline
Gilead Cuts 87% of Arcellx Workforce Following Acquisition

Gilead Cuts 87% of Arcellx Workforce Following Acquisition

Gilead Cuts 87% of Arcellx Workforce Following Acquisition
Trendline Trendline
Vertex Secures Reimbursement for CASGEVY Therapy in Germany for Sickle Cell and Beta Thalassemia

Vertex Secures Reimbursement for CASGEVY Therapy in Germany for Sickle Cell and Beta Thalassemia

Vertex Secures Reimbursement for CASGEVY Therapy in Germany for Sickle Cell and Beta Thalassemia
Trendline Trendline
BioNTech to Close Manufacturing Plants, Impacting 1,860 Jobs

BioNTech to Close Manufacturing Plants, Impacting 1,860 Jobs

BioNTech to Close Manufacturing Plants, Impacting 1,860 Jobs
Reuters Reuters
Pfizer pins post 2028 return to growth on new obesity and cancer drugs

Pfizer pins post 2028 return to growth on new obesity and cancer drugs

By Mariam Sunny and Christy Santhosh May 5 (Reuters) - Pfizer said on Tuesday that it expects to return to stronger growth after 2028, driven by obesity drugs in development, a patent extension for its heart drug Vyndamax and a favorable European court ruling on its COVID-19 vaccine.
Trendline Trendline
Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion
Trendline Trendline
Solid Power Advances Continuous Electrolyte Production Amid Strategic Partnerships

Solid Power Advances Continuous Electrolyte Production Amid Strategic Partnerships

Solid Power Advances Continuous Electrolyte Production Amid Strategic Partnerships
Trendline Trendline
Allarity Therapeutics Advances Stenoparib Toward Phase 3 Development for Ovarian Cancer

Allarity Therapeutics Advances Stenoparib Toward Phase 3 Development for Ovarian Cancer

Allarity Therapeutics Advances Stenoparib Toward Phase 3 Development for Ovarian Cancer
Trendline Trendline
Vion Sells German Slaughterhouse to ABP Food Group Amid Market Exit

Vion Sells German Slaughterhouse to ABP Food Group Amid Market Exit

Vion Sells German Slaughterhouse to ABP Food Group Amid Market Exit
Trendline Trendline
Vir Biotechnology to Present at Bank of America Healthcare Conference

Vir Biotechnology to Present at Bank of America Healthcare Conference

Vir Biotechnology to Present at Bank of America Healthcare Conference